<DOC>
	<DOC>NCT00590096</DOC>
	<brief_summary>I-123-MIBG is used to image patients with neuroblastoma, pheochromocytoma and other neural crest tumors</brief_summary>
	<brief_title>I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma</brief_title>
	<detailed_description>Entry criteria--Histologically documented neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma. Exclusion criteria--Pregnancy Randomization--None Procedure--Patients will receive a dose of I-123-MIBG by intravenous injection. Images will obtained at 18-24 hours after administration of the drug and at 42-48 hours as needed. SSKI will be used to block thyroid uptake of free I-123-iodide</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Pheochromocytoma</mesh_term>
	<criteria>Histologically proven neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Neuroblastoma</keyword>
	<keyword>Pheochromocytoma</keyword>
	<keyword>MIBG</keyword>
</DOC>